GlassScriptPhysician profile
Andrew M Chang
NPI 1003808494
$3,898.11
in general payments reported to CMS, 2019-2025
28 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $188 · 2021: $813 · 2022: $485 · 2023: $659 · 2024: $484 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,186.45 | 2019-2025 | Clareon, Centurion, Unity |
| Sun Pharmaceutical Industries INC. | $401.09 | 2020-2025 | Cequa |
| Abbvie INC. | $289.70 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $212.67 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $207.22 | 2021-2024 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb Americas INC. | $178.06 | 2022-2023 | Vyzulta, Envista Mx60 Iol |
| Stryker Corporation | $161.03 | 2025 | Everest Spinal System |
| Carl Zeiss Meditec, INC. | $133.50 | 2021 | |
| Abbott Laboratories | $125.15 | 2021 | |
| Eyevance Pharmaceuticals LLC | $121.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $118.86 | 2021-2023 | |
| Alcon Research LLC | $118.50 | 2024 | Ngenuity |
| Allergan, INC. | $103.95 | 2020-2022 | |
| Nova Eye, INC. | $97.01 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $85.94 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $47.91 | 2025 | Vevye |
| Alimera Sciences, INC. | $40.27 | 2023 | Iluvien |
| Thea Pharma INC. | $34.58 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $30.19 | 2024 | Lumera 700 |
| Dompe US, INC. | $27.90 | 2025 | Oxervate |
| Omeros Corporation | $27.30 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $24.78 | 2020 | |
| Eyepoint US, INC. | $24.59 | 2023 | |
| Amgen INC. | $23.45 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.66 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $18.66 | 2022 | |
| Oyster Point Pharma, INC. | $15.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.